Chlordecone exposure and women's fertility
KARU-FERTIL: Chlordecone Exposure and Female Fertility
This project will test whether past exposure to the pesticide chlordecone is linked to lower anti-Mullerian hormone (AMH) levels in women aged 18–39 who seek infertility care in Guadeloupe.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 634 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | Female |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe Academic / other |
| Locations | 1 site (Pointe-à-Pitre) |
| Trial ID | NCT07231510 on ClinicalTrials.gov |
What this trial studies
The study will enroll women aged 18–39 who attend the Centre Caribéen de Médecine de la Reproduction (CCMR) at the University Hospital of Guadeloupe and obtain informed consent. Researchers will measure blood chlordecone concentrations and anti-Mullerian hormone (AMH) as a marker of ovarian reserve, and may collect samples for non-targeted environmental exposure testing and vaginal/endometrial microbiome analysis. This is an observational analysis that will look for statistical associations between chlordecone exposure and AMH while accounting for clinical and other exposure factors. Results will help clarify whether persistent environmental contamination in the French West Indies is associated with reduced ovarian reserve.
Who should consider this trial
Good fit: Women aged 18–39 who are consulting for couple infertility at the CCMR (University Hospital of Guadeloupe) and who provide free, informed, written consent.
Not a fit: Women outside the 18–39 age range, those not seeking infertility care at CCMR, or those whose infertility is clearly due to non-environmental causes may not gain direct benefit from this study.
Why it matters
Potential benefit: If a link is confirmed, the results could help identify environmental causes of reduced ovarian reserve and guide public-health actions and fertility counseling for affected women.
How similar studies have performed: Animal studies have consistently reported that chlordecone impairs ovulation and reduces ovarian reserve, but no human studies have yet directly linked chlordecone exposure to female fertility.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged from 18 to 39 years * Consulting for couple infertility at the Centre Caribéen de Médecine de la Reproduction (CCMR, Caribbean Center for Reproductive Medicine) of the University Hospital of Guadeloupe * Free, informed and written consent Exclusion Criteria: * Women aged from 18 to 39 years * Consulting for couple infertility at the Centre Caribéen de Médecine de la Reproduction (CCMR, Caribbean Center for Reproductive Medicine) of the University Hospital of Guadeloupe * Free, informed and written consent
Where this trial is running
Pointe-à-Pitre
- Chu de La Guadeloupe — Pointe-à-Pitre, Guadeloupe (Recruiting)
Study contacts
- Study coordinator: Mélanie petapermal
- Email: melanie.petapermal@chu-guadeloupe.fr
- Phone: +590590934667
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.